Nevro Corp (NYSE:NVRO)
$ 5.08 -0.26 (-4.87%) Market Cap: 189.40 Mil Enterprise Value: 157.99 Mil PE Ratio: 0 PB Ratio: 0.69 GF Score: 44/100

Nevro Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 04:55PM GMT
Release Date Price: $20.16 (+1.05%)
Kallum L Titchmarsh
Morgan Stanley, Research Division - Research Associate

Thanks, everyone, for coming. We are here today with Nevro's CFO, Rod MacLeod. I am Kallum Titchmarsh, medical device analyst here at Morgan Stanley.

Before we get started with the Q&A, I just got to jump into the fund disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So Rob, thanks so much for joining us.

Roderick H. MacLeod
Nevro Corp. - Senior VP & CFO

Great for having us.

Questions & Answers

Kallum L Titchmarsh
Morgan Stanley, Research Division - Research Associate

Obviously, Kevin can't be here today, unfortunately. But wanted to start off really asking, he's been in the job now CEO 5 months or so. What's changed since he's taken

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot